<DOC>
	<DOCNO>NCT00313976</DOCNO>
	<brief_summary>The purpose study evaluate high dose give great efficacy without negative impact adverse event profile patient early secondary progressive Multiple Sclerosis ( SPMS ) .</brief_summary>
	<brief_title>Study Compare Double-dose Betaferon Approved Dose , Patients With Early Secondary Progressive Multiple Sclerosis ( SPMS )</brief_title>
	<detailed_description>The study previously post Schering AG , Germany . Schering AG , Germany rename Bayer Schering Pharma AG , Germany . Bayer Schering Pharma AG , Germany sponsor trial .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Chronic Progressive</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Diagnosis MS less one year longer ten year Disease secondary progressive ( SP ) phase At least one relapse last 3 year Treatment interferon least 6 month Betaferon least 3 month Serious acute heart disease Severe depression Serious acute liver , kidney bone marrow dysfunction Epilepsy adequately treat Pregnancy lactation Alcohol drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Early secondary progressive Multiple Sclerosis</keyword>
</DOC>